Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.
2.

Optimizing asparaginase therapy for acute lymphoblastic leukemia.

Rizzari C, Conter V, StarĂ½ J, Colombini A, Moericke A, Schrappe M.

Curr Opin Oncol. 2013 Mar;25 Suppl 1:S1-9. doi: 10.1097/CCO.0b013e32835d7d85. Review.

PMID:
23380829
3.

Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.

Tzortzatou-Stathopoulou F, Papadopoulou AL, Moschovi M, Botsonis A, Tsangaris GT.

J Pediatr Hematol Oncol. 2001 Dec;23(9):591-7. Review.

PMID:
11902303
4.

PEG-asparaginase.

Fu CH, Sakamoto KM.

Expert Opin Pharmacother. 2007 Aug;8(12):1977-84. Review.

PMID:
17696798
5.

Pegaspargase: a review of clinical studies.

Graham ML.

Adv Drug Deliv Rev. 2003 Sep 26;55(10):1293-302. Review.

PMID:
14499708
6.
7.

Peg-asparaginase for acute lymphoblastic leukemia.

Rytting M.

Expert Opin Biol Ther. 2010 May;10(5):833-9. doi: 10.1517/14712591003769808. Review.

PMID:
20345338
8.

Pegasparaginase: where do we stand?

Zeidan A, Wang ES, Wetzler M.

Expert Opin Biol Ther. 2009 Jan;9(1):111-9. doi: 10.1517/14712590802586058 . Review.

PMID:
19063697
9.

Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.

Hasan H, Shaikh OM, Rassekh SR, Howard AF, Goddard K.

Pediatr Blood Cancer. 2017 Jan;64(1):81-88. doi: 10.1002/pbc.26200. Epub 2016 Aug 31. Review.

PMID:
27578304
10.

L-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia.

Kumar K, Kaur J, Walia S, Pathak T, Aggarwal D.

Leuk Lymphoma. 2014 Feb;55(2):256-62. doi: 10.3109/10428194.2013.803224. Epub 2013 Jun 14. Review.

PMID:
23662993
11.

Pegaspargase: an alternative?

Holle LM.

Ann Pharmacother. 1997 May;31(5):616-24. Review.

PMID:
9161659
12.

Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.

Narta UK, Kanwar SS, Azmi W.

Crit Rev Oncol Hematol. 2007 Mar;61(3):208-21. Epub 2006 Oct 2. Review.

PMID:
17011787
13.

L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.

Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH.

Cancer. 2011 Jan 15;117(2):238-49. doi: 10.1002/cncr.25489. Epub 2010 Sep 7. Review.

14.

[Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].

Thomas X, Cannas G, Chelghoum Y, Gougounon A.

Bull Cancer. 2010 Sep;97(9):1105-17. doi: 10.1684/bdc.2010.1168. Review. French.

15.

L-asparaginase and PEG asparaginase--past, present, and future.

Keating MJ, Holmes R, Lerner S, Ho DH.

Leuk Lymphoma. 1993;10 Suppl:153-7. Review.

PMID:
8481665
16.

Acute lymphoblastic leukemia in a child with nephrotic syndrome.

Bhatia M, Kher K, Minniti CP.

Pediatr Nephrol. 2004 Nov;19(11):1290-3. Epub 2004 Sep 14. Review.

PMID:
15372224
17.
18.
19.

Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.

Hijiya N, van der Sluis IM.

Leuk Lymphoma. 2016;57(4):748-57. doi: 10.3109/10428194.2015.1101098. Epub 2015 Nov 20. Review.

20.

Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.

Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, Kovacsovics T, Litzow M, Rytting M, Borthakur G, Bleyer A.

Leuk Lymphoma. 2011 Dec;52(12):2237-53. doi: 10.3109/10428194.2011.596963. Epub 2011 Aug 10.

PMID:
21827361

Supplemental Content

Support Center